A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease
D9441C00001
Phase 1 other active
Quick answer
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease for Chronic Kidney disease, Atherosclerotic Cardiovascular Disease is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic Kidney disease, Atherosclerotic Cardiovascular Disease
- Phase
- Phase 1
- Modality
- other
- Status
- active